Policosanol-Atorvastatina en el Ictus

1. Goldstein LB, Adams R, Alberts MJ, Kasner SE, et al. American Heart Association; American Stroke Association Stroke Council. Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113:e873–923 2. Furie KL, Kasner SE, Adams R, Albers GW, Bush RL, et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the Prevention of Stroke in patients with stroke or transient ischemic attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227-76. 3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747–1757. 4. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, et al. Population-based study of eventrate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366:1773–1783. 5. Vaartjes I, van Dis I, Grobbee DE, Bots ML. The dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke.BMC Cardiovasc Disord. 2010; 25;10:57. 6. Ministerio de Salud Pública, Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2009, pags 4, 31 – 41, 43, 45, 47, 49, 51, 56, 69, 70 – 74, 82, 94 7. Spence JD. Secondary stroke prevention. Nat Rev Neurol 2010; 6: 477-486 8. Marsh JD, Keyrouz SG. Stroke prevention and treatment. J Am Coll Cardiol. 2010, 24: 56:683-691 9. Dickerson LM, Carek PJ, Quattlebaum RG. Prevention of recurrent ischemic stroke. Am Fam Physician. 2007; 76: 382-388 10. Likosky DJ, Lee K, Brown DM, Amin A, Dressler DD, Krakow D, Rahman S, Jamieson DG. Evidence-based medicine: Review of guidelines and trials in the prevention of secondary stroke. J Hosp Med. 2008; 3:S6-S19 11. Goldstein LB, Adams R, Alberts MJ, et al. American Heart Association; American Stroke Association Stroke Council. Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113:e873–923 12. Klein-Ritter D. An evidence-based review of the AMA/AHA guideline for the primary prevention of ischemic stroke. Geriatrics. 2009, 64:16-20 13. Kunst MM, Schaefer PW. Ischemic stroke. Radiol Clin North Am. 2011; 49:1-26. 14. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis. 2009; 27: 493-501 15. Cucchiara B, Ross M. Transient ischemic attack: risk stratification and treatment. Ann Emerg Med. 2008, 52:S27-S39. 16. Wasserman J, Perry J, Dowlatshahi D, Stotts G, Stiell I, et al. Stratified, urgent care for transient ischemic attack results in low stroke rates. Stroke. 2010; 41:2601-2605 ATI 17. Bejot Y, Caillier M, Ben Salem D, Couvreur G, Rouaud O, et al. Ischemic stroke subtypes and associated risk factors: a French population-based study. J Neurol Neurosurg Psychiatry. 2008;79:1344-1348 18. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903–1913 19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7th report. JAMA. 2003; 289: 2560–2572 20. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease. Lancet. 2008, 371: 1513-1518 21. Pedelty L, Gorelick PB. Management of hypertension and cerebrovascular disease in the elderly. Am J Med. 2008; 121(8 Suppl):S23-31. 22. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002; 62 (suppl 2): 1–9. 23. Kurth T, Kase CS, Berger K, Gaziano JM, Cook NR, Buring JE. Smoking and risk of hemorrhagic stroke in women. Stroke. 2003; 34: 2792–2795 24. Meeuwisse-Pasterkamp SH, van der Klauw MM, Wolffenbuttel BH. Type 2 diabetes mellitus: prevention of macrovascular complications. Expert Rev Cardiovasc Ther. 2008, 6:323-341 25. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004; 27:813–823. 26. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation. 2004; 109: 1729–1734. 27. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989; 320: 904–910. 28. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653 29. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, et al. Asia-Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003; 32: 563–572. 30. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women’s Pooling Project. Stroke. 2002; 33: 1863–1868. 31. Iwashita M, Matsuhista Y, Sasaki J, Arakawa K, Kono S, for the Kyushi Intervention Study (KLIS) Group. Relation of serum total cholesterol and other factors to risk of cerebral infarction in Japanese men with hypercholesterolemia – The Kyushu Lipid Intervention Study-. Circ J 2005, 69: 1 – 6. 32. Bots ML, Elwood P, Nikitin Y, Salonen J, Freire A, Inzitari D, et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health. 2002; 56 (suppl 1): i19–i24 33. Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, et al. Oyabe Study. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study. Stroke. 2003; 34: 863–868 34. Sanossian N, Saver JL, Kim D, Razinia T, Ovbiagele B. Do high-density lipoprotein cholesterol levels influence stroke severity? J Stroke Cerebrovasc Dis. 2006; 15:187-189. 35. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007; 100: S32-40. 36. Toth PP. Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease. Curr Cardiol Rep. 2010; 12:481-487. 37. Koren-Morag N, Tanne D, Graff E, Goldbourt U. Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med. 2002; 162: 993–999 38. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389. 39. Sacks FM, Pfeffer MA, Moyé LA et al., for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1 001-1 009. 40. The Long-Term Intervention with pravastatin in ischaemic disease (LIPID) study group: Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. NEJM 1998, 339: 1349-1357 41. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7-22. 42. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002; 106:1690-1695. 43. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM 1995; 333:1301-1307. 44. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622. 45. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007. 46. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-1630. 47. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; High-dose atorvastatin after Stroke or Transient Ischemic AttackThe Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. N Engl J Med 2006;355:549-559. 48. Connick P, Stacpoole SR. Lipid profile components and risk of ischemic stroke: a role for the pleiotropic effects of statins. Arch Neurol. 2010 Oct;67(10):1284-5 49. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203: 325-330. 50. Broncel M, Koter-Michalak M, Chojnowska-Jezierska J. The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006; 63:738-742. 51. Schalkwijk CG, van Dam B, Stehouwer CDA, van Hinsberg VWM. Mevastatin increases eNO synthase expression and inhibits lipid peroxidation in human endothelial cells. Clinical hemorheology and microcirculation 2007; 37: 179-184 52. Puccetti L, Pasqui AL, Auteri A, Bruni F. Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord. 2005; 5:121-126. 53. Farmak D, Filippatos G, Lainscak M, Parissis JT, Ander SD, Kremastinos DT. Anticoagulants, Antiplatelets, and Statins in Heart Failure. Cardiology Clinics 2008; 26: 49-58. 54. Bloomfield RH, Davenport J, Babikian V, Brass LM, et al. VA-HIT Study Group. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001; 103: 2828–2833 55. Ebrahim S, Sung J, Song YM, Ferrer RL, Lwalor DA, Davey-Smith G. Serum cholesterol, hemorrhagic stroke and myocardial infarction: Korean national heath system prospective cohort study. BMJ. 2006; 333:22-27. 56. Zuliani G, Cherubini A, Atti AR, Blè A, Vavalle C, et al. Low cholesterol levels are associated with short-term mortality in older patients with ischemic stroke. J Gerontol A Biol Sci Med Sci. 2004; 59:293-297 57. Büdingen HC, Baumgartner RW, Baumann CR, Rousson V, Siegel AM, Georgiadis D. Serum cholesterol levels do not influence outcome or recovery in acute ischemic stroke. Neurol Res. 2007 Aug 31 58. Olsen TS, Christensen RH, Kammersgaard LP, Andersen KK. Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality: ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. Stroke. 2007, 38:2646-2651. 59. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. NEJM 2001; 344: 3–10. 60. Nagata C, Takatsuka N, Shimizu N, Shimizu H. Sodium intake and risk of death from stroke in Japanese men and women. Stroke. 2004; 35: 1543–1547 61. Sauvaget C, Nagano J, Allen N, Kodama K. Vegetable and fruit intake and stroke mortality in the Hiroshima/Nagasaki Life Span Study. Stroke. 2003; 34: 2355–2360. 62. Sauvaget C, Nagano J, Hayashi M, Yamada M. Animal protein, animal fat, and cholesterol intakes and risk of cerebral infarction mortality in the adult health study. Stroke. 2004; 35: 1531–1537. 63. Assanelli D, Cottarelli C, Salvadori G, et al. Work, cardiopathy, and sports. Med Lav. 2004; 95(2):119-23. 64. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, et al. Body mass index and the risk of stroke in men. Arch Intern Med. 2002; 162: 2557–2562. 65. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, et al.; Northern Manhattan Stroke Study. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003; 34: 1586–1592 66. Isozumi K. Obesity as a risk factor for cerebrovascular disease. Keio J Med. 2004; 53: 7–11 67. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. NEJM 2002; 347: 1825–1833 68. Hart RG, Halperin JL, Pearce L, Anderson DC, Kronmal RA, et al. Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med. 2003; 138: 831–838 69. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (3 suppl): 429S–456S 70. Oden A, Fahlen M, Hart R. Optimal INR for prevention of stroke and mortality in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117:493–9. 71. Nadareishvili ZG, Rothwell PM, Beletsky V, Pagniello A, Norris JW. Long-term risk of stroke and other vascular events in patients with asymptomatic carotid artery stenosis. Arch Neurol. 2002; 59: 1162–1166 72. Halliday A, Mansfield A, Marro J, Peto C, Peto R, et al. Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial Lancet. 2004; 363: 1491–1502. 73. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288: 321–333 74. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. A randomized controlled trial. JAMA 2002, 288: 2432 - 2440 75. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 2002; 324: 71-86. 76. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs. 2002; 1: 273 – 288 77. Habib GB. Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy. Clin Cardiol. 2006; 29:244-248. 78. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA. 2003; 289: 579–588 79. Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke. 2003; 34: 632–636 80. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004; 291: 565–575. 81. Koçer A, Canbulat C, Gözke E.C-reactive protein is an indicator for fatal outcomes in first-time stroke patients. Med Sci Monit. 2005, 11: CR540-544. 82. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003; 14: 361–366 83. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2000; 2:36-46. 84. Ranga GS, Kalra OP, Tandon H, Gambhir JK, Mehrotra G. Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2007, 16: 220-224 85. Kurl S, Laukkanen J, Niskanen L, Laaksonen D; Sivenius J, et al. Metabolic Syndrome and the Risk of Stroke in Middle-Aged Men. Stroke. 2006; 37: 806-811 86. Skvortsova VI, Nartsissov IaR, Bodykhov MK, Kichuk IV, Prianikova NA, et al. Oxidative stress and oxygen status in ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2007; 107:30-36. 87. Kim NS, Kang K, Cha MH, Kang BJ, Moon J, et al. Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophys Res Commun. 2007; 364:157-162. 88. Ferretti G, Bacchetti T, Masciangelo S, Nanetti L, Mazzanti L, et al. Lipid peroxidation in stroke patients. Clin Chem Lab Med. 2008; 46:113-117. 89. Willcox BJ, Curb JD, Rodriguez BL Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol. 2008; 101(10A):75D-86D. 90. Emdin, M; Passino C, Donato L, Paolicchi A; Pompella A Serum Gamma-Glutamyltransferase as a Risk Factor of Ischemic Stroke Might Be Independent of Alcohol Consumption. Stroke. 2002; 33:1163, 1164 91. Sacco RL, Adams R, Alberts G, Alberts MJ, Benavente O, et al. Guidelines for stroke prevention of stroke in patients with ischemic stroke or transient isquemic attack. Stroke 2006; 37: 577-617. 92. Dickerson LM, Carek PJ, Quattlebaum RG. Prevention of recurrent ischemic stroke. Am Fam Physician 2007; 76:382-388 93. Phillips RA. A review of therapeutic strategies for risk reduction of recurrent stroke. Prog Cardiovasc Dis. 2008; 50: 264-273 94. Cornett O, Ocava LC, Singh M, Malhotra S, Rosenbaum DM. Antithrombotic and thrombolytic therapy for ischemic stroke. Cardiol Clin. 2008; 26:251-65, vii 95. Field TS, Benavente OR. Current status of antiplatelet agents to prevent stroke. Curr Neurol Neurosci Rep. 2010, Nov 23. [Epub ahead of print] 96. Segall L, Oprisiu R, Fournier A, Covic A. Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials. J Nephrol. 2008; 21:374-83. 97. Ovbiagele B. Antiplatelet therapy in management of transient ischemic attack: overview and evidence-based rationale. J Emerg Med. 2008, 34: 389-396 98. Inzitari D, Piccardi B, Sarti C. A critical review of aspirin in the secondary prevention of noncardioembolic ischaemic stroke. Int J Stroke. 2010, 5:306-318. 99. Patrono C, Coller B, Dalen JE, Fitzgerald GA, Fuster V, Gent M, et al. Platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 2001, 119: 39S – 63S 100. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008; 121:43-49. 101. Sanmuganathan, P. Ghahramani, P. Jackson, P. Ramsay, L. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373:1849-1860. 102. Cavallari LH, Helgason CM, Brace LD, Viana MA, Nutescu EA. Sex difference in the antiplatelet effect of aspirin in patients with stroke. Ann Pharmacother. 2006; 40:812-817. 103. Sanmuganathan, P. Ghahramani, P. Jackson, P. Ramsay, L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295:306-313. 104. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007, 28:1925-1927 105. Colwell JA, Aspirin for Primary Prevention of Cardiovascular Events in Diabetes. Diabetes Care 2003, 26:3349-3350 106. Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, et al. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging 2006; 23: 559-567 107. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008, 28: s25-32 108. Bugnicourt JM, Roussel B, Garcia PY, Canaple S, Lamy C, Godefroy O. Aspirin non-responder status and early neurological deterioration: A prospective study. Clin Neurol Neurosurg. 2010 Dec 7. [Epub ahead of print] 109. Nema H, Kato M. Investigation of gastroduodenal mucosal injuries caused by low-dose aspirin therapy in patients with cerebral infarction. J Gastroenterol Hepatol. 2010, 25 Suppl 1:S119-21. 110. Manson SC, Benedict A, Pan F, Wittrup-Jensen KU, Fendrick AM. Potential economic impact of increasing low dose aspirin usage on CVD in the US. Curr Med Res Opin. 2010; 26:2365-2373. 111. Gebel JM. Heterogeneity and safety of antipletlet therapy in cardiovascular disease. 2010: 115 - 124 112. Cannon CP. Clopidogrel: who, when, and how? Rev Cardiovasc Med. 2007; 8 Suppl 3:S27-34 113. Hassan A, Zacharatos H, Suri M, Qureshi A. Drug evaluation of clopidogrel in patients with ischemic stroke. Expert Opin Pharmacother. 2007, 8:2825-2838. 114. Gent M, Beaumont D, Blanchard J, et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1338. 115. Abbate R, Crea F, De Servi S, Filippi E, Gensini GF, et al. Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel. G Ital Cardiol (Rome). 2010; 11:127-137. 116. Mousa SA, Jeske WP, Fareed J. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clin Appl Thromb Hemost. 2010; 16:170-176. 117. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996; 143: 1-13. 118. Leonardi-Bee J, Bath PM, Bousser MG, Davalos A, Diener H; et al on behalf of the Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events. A meta-analysis of individual patient data from randomized controlled trials Stroke 2005;36:162 - 170 119. Abciximab in acute ischemic stroke. A randomised, double-blind, placebo-controlled, dose-escalation study. The Abciximab in Ischemic Stroke Investigators. Stroke 2000; 31: 601-609. 120. Curtis BR, Swyers J, Divgi A, et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054-2059. 121. Urbano LA, Bogousslavsky J. Antiplatelet drugs in ischemic stroke prevention: from monotherapy to combined treatment. Cerebrovascular Diseases 2004;17 (Suppl. 1):74-80 122. Diener HC. Antiplatelet agents and randomized trials. Rev Neurol Dis. 2007; 4:177-183 123. Schwartz NE, Albers GW. Is there a role for combinations of antiplatelet agents in stroke prevention? Curr Treat Options Neurol 2007, 9:442-450. 124. Schwartz NE, Albers GW. Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?. Curr Neurol Neurosci Rep 2008, 8:29-34. 125. Bernstein RA. Antiplatelet agents for secondary prevention of stroke Curr Treat Options Cardiovasc Med 2008, 10:223-228 126. Grines C, Cho L. Atherothrombotic disease and the role of antiplatelet therapy in women. J Womens Health (Larchmt). 2008; 17: 35-46 127. Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J. 2008, 29:1086-1092. 128. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 2008; 101:960-966 129. Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother 2008; 42:550-557 130. Fisher M, Davalos A. The MATCH Study results in the context of Secondary Stroke Prevention. Stroke. 2004;35:2609 131. Bhatt DL, Fox K, Hacke W, Berger P, Black H, et al. The Clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) study. N Engl J Med 2006; 354:1706–1717. 132. Fintel DJ. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists. Clin Cardiol 2007, 30:604-614 133. Gorter JW, De Schryver EL, Algra A. Secondary prevention after ischemic cerebral infarct. The ESPRIT Study: low dose anticoagulation, combined therapy with acetylsalicylic acid/dipyridamole or monotherapy with acetylsalicylic acid? Nervenarzt. 1999; 70:368-370. 134. Lutsep HL. New developments in secondary stroke prevention: impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on clinical management. J Stroke Cerebrovasc Dis 2007; 16:263-267. 135. Pha H, Lj G, Pmw BM, HcD, B GC, Fm Y, AA. Dipyridamole plus aspirin versus aspirin alone in the secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry. 2008, Jun 5. 136. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39:1358-1363 137. Marissal JP, Selke B. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France. Pharmacoeconomics 2004; 22:661-670 138. Halkes PH, Algra A. Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient? Cerebrovasc Dis. 2007; 24 Suppl 1:107-111. 139. Franks ZG, Campbell RA, Weyrich AS, Rondina MT. Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke. Ann N Y Acad Sci. 2010;1207:11-17. 140. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999; 30: 1223–1229 141. De Backer G, Ambrosioni E, Borch-Johnssen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). J. Eur. Heart 2003, 24: 1601-1610. 142. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989; 320: 904–910. 143. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653 144. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, et al. Asia-Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003; 32: 563–572. 145. Athyros VG, Kakafika AI, Tziomalos K, Papageorgiou AA, Karagiannis A. Statins for the prevention of first or recurrent stroke. Curr Vasc Pharmacol. 2008, 6:124-133 146. Nassief A, Marsh JD Statin therapy for stroke prevention. Stroke. 2008; 39:1042-1048 147. Kiranbir J, Finlay MA. Cholesterol lowering for secondary prevention: What statin dose should we use? Vasc Health Risk Manag. 2007 3: 615–627 148. Schwertz DW, Badellino KO. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review. J Cardiovasc Nurs. 2008; 23: 8-13 149. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387–392 150. Sever PS, Dahof B, Poulter NR, Wedel H, Beevers G, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361:1149-58. 151. Hitman GA, Colhoun H, Newman C, Szarek M, Betteridge DJ, Durrington PN, for the CARDS Investigators. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med. 2007, 24:1313-1321 152. Amarenco P. Atorvastatin in prevention of stroke and transient ischaemic attack. Expert Opin Pharmacother. 2007; 8:2789-2797. 153. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2007, 62:879-887 154. Walker DB, Jacobson TA. Initiating statins in the elderly: the evolving challenge. Curr Opin Endocrinol Diabetes Obes. 2008; 15:182-187 155. Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther. 2008; 6:95-107 156. Preobrazhenskiĭ DV, Sidorenko BA, Pataraia SA, Vyshinskaia ID, Borisenko OV. Hypercholesterolemia in men and women of various ages. Part II. The problem of efficacy and safety of statins. Kardiologiia. 2007; 47:75-85 157. Preobrazhenskiĭ DV, Sidorenko BA, Pataraia SA, Vyshinskaia ID, Borisenko OV. Hypercholesterolemia in men and women of various ages. Part II. The problem of efficacy and safety of statins. Kardiologiia. 2007; 47:75-85 158. Majaz Moonis, Kevin Kane, Ute Schwiderski, Bobby W. Sandage, Marc Fisher. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke. 2005; 36:1298-300 159. Reeves MJ, Gargano JW, Luo Z, Mullard AJ, Jacobs BS, Majid A; Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators. Effect of pretreatment with statins on ischemic stroke outcomes. Stroke 2008, 39:1779-1785 160. Lampl Y, Lorberboym M, Gilad R, Vysberg I, Tikozky A, Sadeh M, Boaz M. Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin. Clin Neuropharmacol. 2010 May;33(3):129-34. 161. Lorna M, Gibson LM, Brazzelli M, Thomas BM, Peter AG. A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full. Trials. 2010; 11: 43. 162. The National Institute for Neurological Desorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333: 1581-1587. 163. Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB, et al. Intravenous Tissue Plasminogen Activator for acute ischemic stroke. Feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998, 29: 18-22. 164. Grond M, Neveling M, Lechleuthner A, Schneweis S, Heiss WD. Early Intravenous Thrombolysis for Acute Ischemic Stroke in a community-based approach. Stroke 1998; 29:1544-1549 165. Albers GW, Bates VE, Clark WM. Intravenous tissue-type plasminogen activator for treatment of acute strocke: The standard treatment with alteplase to reverse stroke (STARS) study. JAMA 2000; 283: 1145-1150. 166. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274: 1017-1025 167. Hacke W, Kaste M, Fieschi C, et al. Randomized, double blind, placebo controlled trial of trombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II) Second European Australasian Cooperative Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251. 168. Clark WM, Wissman S, Alber GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic Stroke 3 to 5 hours after symptoms onset. The ATLANTIS Trial. JAMA 1999; 282: 2019-2026. 169. Furlan AJ,Higashida R, Wescheler L, et al. PROACT II: recombinant prourokinase (R-proUK) in acute cerebral thromboembolism initial trial results. Stroke 1999; 30: 234. 170. Mas R. Policosanol Drugs of the Future 2000, 25: 569-586 171. Menéndez R., Arruzazabala ML, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Brit J Nutr, 1997, 77: 923-932. 172. Menéndez R., Fernández I., del Río A., et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res, 1994, 27: 199-203. 173. Menéndez R., Amor A.M., González R., et al. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res, 1996, 29: 253-257. 174. Menéndez R, Amor A, Rodeiro I, et al: Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res 2001, 175. Singh DK, Li L, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinases. J Pharmacol Exp Ther 2006, 106. 107- 144 176. Oliaro Rosso S, Calcio E, Mantegna S, et al. Regulation of HMGCoA reductase by policosanol and octacosadienol, a new synthetic analogue of octacosanol. Lipids 2009, DOI 10.1007/s11745-009-3338-y 177. Banerjee S, Porter TD. Tea and policosanol act through different mechanisms to activate AMP-kinase and suppress HMG-CoA reductase to inhibit cholesterol synthesis. Proceedings of the FASEB meeting. FASEB J 2010, p 541.23 178. Menendez R, Marrero D, Mas R et al. In vitro and in vivo study of octacosanol metabolism. Arch Med Res. 2005, 36:113-119. 179. Mesa AR., Más R., Noa M., et al. Toxicity of policosanol in Beagle dogs: one year study. Toxicol Lett, 1994, 73: 81-90. 180. Rodríguez C, Mesa R., Más R., et al. Effect of policosanol chronically administered in male monkeys (Macaca arctoides). Fd Chem Toxicol, 1994, 32: 565-575. 181. Arruzazabala ML, Carbajal D, Más R, et al. Effects of policosanol on platelet aggregation in rats. Thromb Res, 1992, 69: 321-327. 182. Arruzazabala ML., Carbajal D, Molina V et al. Effect of policosanol on cerebral ischemia in Mongolian gerbils: Role of prostacyclin and thromboxane A2. Prostag, Leuk & Ess Fatty Acids, 1993, 49: 695-697. 183. Arruzazabala M.L., Carbajal D., Molina V., et al. Estudio farmacológico de la interacción entre el policosanol y la aspirina en animales de experimentación. Rev Iberoamer Tromb Hemost, 1992, 5: 17-20. 184. Menéndez R., Fraga V, Amor AM, et al. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Behav 1999, 67: 1-7 185. Ohta Y, Ohashi K, Mansura T. Octacosanol attenuates disrupted hepatic reactive oxygen species metabolism associated with acute liver injury progression in rats intoxicated with carbon tetrachloride. J Clin Biochem Nutr. 2008; 42: 118–125 186. Noa, Mas R Effect of policosanol on atherosclerotic plaque composition on aortas of Macaca arctoides monkeys. Arch Med Res 2005, 36: 441-447. 187. Noa M, Más R, Mesa R: Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. Intern J Cardiol 1999, 67: 125-132 188. Noa M; Mas R; Mesa R: A comparative study of policosanol versus lovastatin on intimal thickening in rabbit cuffed carotid artery Pharmacol Res 2001, 43: 31-37 189. Noa M, Más R, Mesa AR. Effect of policosanol in circulating endothelial cell in experimental models in Sprague-Dawley rats and in rabbits. J Pharm Pharmacol 1997, 49: 999-1002. 190. Noa M, Más R, de la Rosa MC, et al. Effect of policosanol on lipofundin-induced atherosclerotic lesions in rats. J Pharm Pharmacol, 1995, 47: 289-291. 191. Noa M., la Rosa MC, Mas R. Effect of policosanol on foam cell formation in carrageenan-induced granulomas in rats. J Pharm Pharmacol, 1996, 48: 306-309. 192. Arruzazabala ML, Noa M, Menéndez R., et al. Effects of policosanol on atherosclerosis lesions in rabbits with exogenous hypercholesterolemia. Brazil J Med Biol Res 2000, 33: 835 – 840 193. Setnikar I, Senin P, Rovati LC Antiatherosclerotic efficacy of policosanol, red yeast rice extract and astaxanthin in the rabbit. Arzneimittelforschung. 2005, 55:312-317. 194. Carbajal D, Arruzazabala ML, Más R, et al. Effects of policosanol of experimental thrombosis models. Prostag, Leuk & Ess Fatty Acids, 1994, 50: 249-251. 195. Arruzazabala ML., Carbajal D, Molina V et al. Effect of policosanol on cerebral ischemia in Mongolian gerbils: Role of prostacyclin and thromboxane A2. Prostag, Leuk & Ess Fatty Acids, 1993, 49: 695-697. 196. Borg J, Toazara J, Hietter H. et al. Neurotrophic effects of naturally occurring long-chain fatty alcohols in cultured CNS neurons. FEBS Lett 1987, 213: 406 – 410 197. Borg J. The neurotrophic factor, n-hexacosanol, reduces the neuronal damage induced by the neurotoxin, kainic acid. J Neuros Res. 1991; 29: 62 -67 198. Wang T, Liu YY, Wang X, Yang N, Zhu HB, Zuo PP. Protective effects of octacosanol on 6-hydroxydopamine-induced parkinsonism in rats via regulation of proNGF and NGF signalling. Acta Pharmacol Sin 2010, 31: 765 – 774. 199. Menéndez R, Más R, Amor AM Fernández JC, Illnait J, et al: Effects of policosanol treatment on the susceptibility of low-density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Brit. J. Clin. Pharmacol. 2000, 50: 255-262. 200. Castano G, Mas R, Fernandez L et al. Effects of policosanol on patients with borderline to mildly increased serum cholesterol levels: A prospective, double-blinded placebo-controlled study. Curr Ther Res Clin & Exptl 2003, 64 522 – 537 201. Aneiros E, Calderón B, Más R, Illnait J, Fernández L. et al: Effects of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res Clin & Exptl 1993, 54: 304-312 202. Soltero I, Fuenmayor I, Colmenares J, Arias F: Ensayo doble ciego para la evaluación del policosanol en el tratamiento de la hiperlipoproteinemia tipo II. Arch Venezol Farmacol Terap 1993, 12: 65-70 203. Soltero I, Fuenmayor I, Colmenares J: Estudio comparativo doble ciego de la eficacia y tolerancia del policosanol vs bezafibrato en pacientes con hiperlipidemia tipo II. Arch Venezol Farmacol Terap 1993, 12: 71-76. 204. Pons P, Rodríguez M, Robaina C, Illnait J, Fernández L et al: Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res 1994, 14: 27-33 205. Aneiros E, Más R, Calderón B, Illnait J, Fernández L et al: Effect of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res Clin & Exptl 1995, 56: 176-182 206. Campilongo R, Sandini P, Feldman R et al: Eficacia, seguridad y tolerabilidad del policosanol en pacientes argentinos con hipercolesterolemia tipo II. Estudio abierto. La Prensa Médica Argentina 1996, 83: 665-672. 207. Benítez M, Romero C, Más R, Fernández L. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res Clin &Exptl 1997, 58: 859-867 208. Prat H, Roman O, Pino E. Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. Rev Med Chil. 1999, 127: 286-294. 209. Alcocer A, Fernández L, Campos E, Más R.: A comparative study of policosanol vs acipimox in patients with type II hypercholesterolemia. Int J Tissue React 1999, 21: 57-64 210. Nikitin IP, Slepchenko NV, Gratsianskii NA et al: Results of the multicenter controlled study of the hypolipidemic policosanol in Russia. Ter Arkh. 2000, 72: 7 – 10. 211. Castaño G, Mas R, Fernández L, Illnait J, Fernández JC et al: Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: A 6 months double-blind study. Int J Clin Pharmacol Res. 2001, 21 43-58 212. Figuera SR, Soto I, Lara A, et al. Estudio comparativo de la eficacia y tolerancia del policosanol en pacientes con hipercolesterolemia Tipo II. Arch Venezol Farmacol Terap 2001, 20: 88 – 91 213. Pella D, Rybar R, Trejbal D. Liecba dyslipidemic statiny a fibraty? je policosanol-bezpecne a efectivNe hypolipidemikum? Medicinsky Monitor. Slovenska Lekakska Spolocnost 2002, 7 – 9 214. Wright CM, Zieike JC, Whayne TF. Policosanol, an aliphatic alcohol sugarcane derivative. Use in patients intolerant or inadequately responsive to statin therapy. Int J Angiol 2004, 13: 173 – 175 215. Wang Y, Yuan-nan KE, Wang JL, et al. Efficacy and safety of policosanol and pravastatin in the treatment of hyperlipidemia in Chinese patients. Chin J New Drugs Clin Res 2008, 2: 27 – 35 216. Chen JT, Wesley R, Shamburek RD et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005; 25:171-183 217. Castaño G, Más R, Fernández L, Illnait J, et al: Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000, 13: 187-195. 218. Mirkin A, Mas R, Martinto M, Irico L, et al Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int.J Clin Pharmacol Res 2001, 21: 31-42. 219. Más R, Castaño G, Illnait J, Fernández L, Fernández J et al: Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999, 65: 439-447 220. Menéndez R, Más R, Amor A, González R, Fernández JC et al: Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation. A Randomised, Double-Blinded Pilot Study. Curr Ther Res Clin &Exptl 2000, 61: 609-620 221. Ortensi G, Gladstein H, Valli H, Tesone PA: A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res Clin & Exptl 1997, 58: 390-401 222. Castaño G, Más R, Arruzazabala ML, et al: Effects of policosanol and pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int. J. Clin Pharm. Res. 1999, 19: 105-116 223. Castaño G, Más R, Fernández JC, Illnait J, Fernández L et al: Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol (Med Sci) 2000, 3: M186 – M 192 224. Fernández JC, Más R, Castaño G, et al: Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women. Clin Drug Invest 2001 21: 103-113 225. Castaño G, Mas R, Fernández L, et al. Comparison of the efficacy, safety and tolerability of policosanol versus atorvastatin in elderly patients with Type II hypercholesterolemia. Drugs & Aging 2002, 20: 153 – 163 226. Zardoya R, Tula L, Castaño G, et al: Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function. Curr Ther Res Clin & Exptl 1996, 57: 568-577. 227. Musto D, Martorelli L, Russo M, Esposito G, Amato MR, et al. The efficacy of policosanols in the treatment of associated hyperlipidemia in patients with non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2010; 56:389-395. 228. Torres O, Agramonte A, Illnait J, Fernández L, Mas R: Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995, 18: 393-397 229. Crespo N, Alvarez R, Más R, Illnait J, Fernández L et al: Effect of policosanol on patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia. Curr Ther Res Clin &Exptl 1997, 58: 44-51 230. Crespo N; Illnait J; Mas R; et al: Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999, 19: 105-116 231. Castaño G, Menéndez R, Más R, et al: Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated to type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002, 22: 89 – 100 232. Castaño G, Fernández L, Mas R, et al: Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation on patients with dyslipidemia and Type 2 diabetes mellitus. Clin Drug Invest 2003, 23: 639-650. 233. Pons P, Rodríguez M, Más R, et al: One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res Clin & Exptl 1994, 55: 1 084-1092 234. Canetti M, Morera M, Illnait J, Mas R, Fernández L et al One-year study on the effect of policosanol (5 mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv Ther 1995, 12: 245-254 235. Canetti M, Morera M, Illnait J, Mas R, Fernández L et al: A two years study on the efficacy and tolerability of policosanol in patients with type II Int J Clin Pharmacol Res 1995, 15: 159-165 236. Castaño G, Canetti M, Morera M, Illnait J, Fernández L et al: Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12 months study. Curr Ther Res Clin & Exptl 1995, 56: 819-828 237. Canetti M, Morera MS, Más R, Illnait J, Fernández L et al: Effects of policosanol on primary hypercholesterolemia: A 3-year open follow-up. Curr Ther Res Clin & Exptl 1997, 58: 868-875 238. Mas R, Castaño G, Fernández L, Illnait J, Fernández J, et al: Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin Drug Invest 2001, 21: 485-497 239. Castaño G, Mas R, Fernández J, Fernández L, Illnait J, et al: Effects of policosanol in older patients with hypertension and Type II hypercholesterolemia. Drugs R&D 2002, 3: 159 – 172. 240. Castaño G, Mas R, Gamez R. et al. Concomitant use of policosanol and beta-blockers in older patients. Int J Clin Pharmacol Res. 2004; 24:65-77 241. Castaño G, Nodarse M, Más R, et al: Estudio comparativo de la eficacia y tolerabilidad del policosanol, la simvastatina y de su terapia combinada en el tratamiento de la hipercolesterolemia tipo II. Rev CENIC Cien Biol 1998, 29: 9-15. 242. Marcello S, Gladstein J, Tesone P, Más R: Effects of combination policosanol-bezafibrate therapy in patients with combined dislipidemia: A pilot study. Curr Ther Res Clin &Exptl 2000, 61: 346-357. 243. Castaño, G, Fernández L, Mas R, et al. Effects of policosanol added to Omega-3 fatty acids (FA) therapy on lipid profile of patients with Type II hypercholesterolemia Drugs R&D 2005, 6: 207 – 219 244. Valdés S, Arruzazabala ML, Carbajal D, Molina V, Mas R. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res 1996, XVI: 67-72 245. Scazziota A, Pons S, Altman R: Efecto del policosanol sobre la función de las plaquetas en voluntarios sanos. Rev Iberoam Trombo Hemost 1996, 9: 58-62 246. Arruzazabala ML, Valdés S, Mas R, Carbajal D, Molina V: Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 1996, 34: 181-185 247. Arruzazabala ML, Molina V, Mas R Carbajal D, Fernández L. Antiplatelet effects of policosanol 20 and 40 mg/d in healthy volunteers and dyslipidemic patients. Clin Exp Pharmacol Physiol 2002, 29: 891 – 897 248. Arruzazabala ML, Valdés S, Mas R, Carbajal D, Molina V. Comparative study of policosanol, aspirin and the combination of policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1997, 36: 293-297 249. Arruzazabala ML, Más R, Molina V, Carbajal D, Fernández L. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tiss React 1998, 20: 119-124 250. Castaño G, Arruzazabala ML, Fernández L et al: Effects of combination treatment with policosanol and Omega fatty acids on platelet aggregation: a randomised, double blind clinical study. Curr Ther Res Clin &Exptl 2006, 62: 174 - 192 251. Carbajal D, Arruzazabala ML, Valdés S, Mas R: Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostagl Leukotr Essent Fatty Acids 1998, 58: 61-64 252. Castaño G, Más R, Fernández L et al: A double-blind placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 1999, 50: 123-130. 253. Castaño G, Mas R, Fernández L et al: A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001, 52: 115-125 254. Castaño G, Mas R, Fernández L et al: Effects of policosanol and lovastatin in patients with intermittent claudication: A double-blind comparative pilot study Angiology 2003, 54: 25 - 38 255. Castaño G, Más R, Gámez, R et al. Effects of policosanol and ticlopidine in patients with intermittent claudication: A double-blinded pilot comparative study. Angiology 2003, 55: 361 – 371 256. Illnait J, Castaño G, Alvarez E., Fernandez L., Mas R., Mendoza S., Gamez R. Effects of policosanol (10 mg) vs aspirin (100 mg/d) in patients with intermittent claudication: a 10- week, randomized, comparative study. Angiology 2008, 59: 269-77. 257. Más R. Rivas P, Izquierdo JE et al. Pharmacoepidemiologic study of policosanol. Curr Ther Res 1999, 60: 458-467 258. Batista J, Stusser RJ, Padrón R, et al: Functional improvement in coronary artery disease after 20 month of lipid-lowering therapy with policosanol. Adv Ther 1996, 13: 137-148 259. Moreno FL, Lagomasino AL, Ramírez M, et al. Utilidad del policosanol en pacientes obesos sometidos a revascularización miocárdica quirúrgica. 4th Virtual Congress of Cardiology, October 2005 260. Mas R, Castaño G, Fernández J, et al. Effects of policosanol on morbidity and mortality in older hypercholesterolemic patients. J Am Coll Cardiol. 2002; 39 (Suppl B):429B. 261. Batista J, Stusser R, Penichet M, Uguet E: Doppler-ultrasound pilot study of the effects of long-term policosanol therapy on carotid-vertebral atherosclerosis. Curr Ther Res 1995, 56: 906-914 262. Ortega L, Sánchez J, Más R, et al. Effects of policosanol on patients with ischemic stroke: A pilot open study. J Med Food 2006, 9: 378–382 263. Sanchez J, Mas R, Mendoza S., Fernández J, Ruiz D. Efectos del policosanol en pacientes con ictus y ataque transitório de isquemia previo: seguimiento a largo plazo. Rev CENIC Cien Biol 2010, 41: 23-29. 264. Sanchez J, Mas R, Fernández L, Illnait J, Arruzazabala ML, Noa M, Molina V, Carvajal D, Fernández JC, Mendoza S., Mesa M, Mendoza N. Efectos del policosanol sobre la recuperación neurológica y la agregación plaquetaria en pacientes con ictus isquémico. Datos de archivo 265. Sanchez J, Mas R, Fernández L, Illnait J, Arruzazabala ML, Noa M, Molina V, Carvajal D, Fernández JC, Mendoza S., Mesa M, Mendoza N. Efectos del policosanol sobre la recuperación neurológica y variables oxidativas en pacientes con ictus isquémico. Datos de archivo 266. González R, Paz L, Efectos del policosanol en pacientes con ictus isquémico. Datos de archivo 267. Gámez R, Alemán C, Mas R, et al: A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague Dawley rats. J Med Food 2001, 4: 57-66 268. Alemán C, Más R, Hernández C, et al. A 12 months study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett, 1994, 70: 77-87. 269. Fernández I , Rendón A, Noa M, Mas R, Laguna A.. Study of policosanol effects on mice germ cells. Rev. CNIC, Cien. Biol 2006, 37: 3 - 7 270. Fernández I, Alfonso JL, Acosta PC. In vitro mutagenic evaluation of policosanol. Rev CNIC Cien Biol 2006, 37: 9 - 12 271. Rodríguez M, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog, Carcinog Mutag, 1994, 14: 107-113. 272. Rodríguez M, Sánchez M, García H. Multigeneration reproduction study of policosanol in rats. Toxicol Lett, 1997, 90: 97-106. 273. Alemán C, Más R., Noa M., et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 months study. Teratog, Carcinog Mutag, 1994, 14: 239-249. 274. Alemán CL, Noa M, Cerejido E, et al. Carcinogenicity of policosanol in mice: A 18 months study. Food Chem Toxicol, 1995, 33: 573-578. 275. Fernández L, Más R, Illnait J et al: Policosanol: results of a post-marketing surveillance control on 27 879 cases. Curr Ther Res 1998, 59: 717-722. 276. Fernández S, Mas R, Gamez, R et al. A pharmacological surveillance of policosanol tolerability in the elderly. Am J Ger Pharmacotherapy 2004, 2: 219 – 229. 277. Requerimientos para la notificacion y el reporte de eventos adversos graves e inesperados en los ensayos clínicos. Regulacion No. 45-2007. CECMED, 2007. 278. Arboix A, García-Eroles L, Oliveres M, Targa C, Balcells M, Massons J. Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? BMC Neurol. 2010; 10: 47. 279. Kate M, Sylaja PN, Chandrasekharan K, Balakrishnan R, Sarma S, Pandian JD. Early risk and predictors of cerebrovascular and cardiovascular events in transient ischemic attack and minor ischemic stroke. Neurol India 2012; 60(2):165-7. 280. Mahoney Fl, Barthel DW:Functional evaluation: the Barthel Index. Md State Med J 14:2, 1965. 281. de Oliveira R, Cacho EW, Borges G. Post-stroke motor and functional evaluations: a clinical correlation using Fugl-Meyer assessment scale, Berg balance scale and Barthel index. Arq Neuropsiquiatr. 2006 Sep;64(3B):731-5. 282. Barrero CL, García S, Ojeda A. Índice de Barthel (IB): Un instrumento esencial para la evaluación funcional y la rehabilitación. Plasticidad y Restauración Neurológica 2005; 4(1-2): 81-85 283. Jeong BO, Kang HJ, Bae KY, Kim SW, Kim JM, Shin IS, Kim JT, Park MS, Cho KH, Yoon JS. Determinants of quality of life in the acute stage following stroke. Psychiatry Investig 2012; 9(2):127-33 284. Friedewald WT, Levy RI; Friederickson SD (1972): Estimation of the concentration of low-density.lipoprotein cholesterol in plasma without of the preparative ultracentrifuge. Clin Chem, 1972 18: 499-502.